A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

##STR00001##

A preparation method for salicylamine acetate, comprising preparing an amino-protected intermediate from salicylaldehyde, and reacting the intermediate with acetic acid to prepare an acetate.

A preparation method for salicylamine acetate, comprising preparing an amino-protected intermediate from salicylaldehyde, and reacting the intermediate with acetic acid to prepare an acetate.

Disclosed herein are derivatives of phenolic and melamine compounds, methods of making these derivatives, and methods of using them. The compounds include phenolic and melamine compounds with multi-functional acrylate groups, polyethylene glycol and amino groups. The compounds may be cured to form resins that may be used in a variety of applications, such as paints, hydrogels, polyacrylate super absorbent polymers (SAPs), adhesives, composites, sealants, fillers, fire retardants, crosslinking agents, and the like.

Disclosed herein are derivatives of phenolic and melamine compounds, methods of making these derivatives, and methods of using them. The compounds include phenolic and melamine compounds with multi-functional acrylate groups, polyethylene glycol and amino groups. The compounds may be cured to form resins that may be used in a variety of applications, such as paints, hydrogels, polyacrylate super absorbent polymers (SAPs), adhesives, composites, sealants, fillers, fire retardants, crosslinking agents, and the like.

Disclosed is an anti-oxidation stabilizer, which has the following structure (A), wherein R1 is a connection chain, and the connection chain is a fatty chain, an aromatic structural chain or a fatty and aromatic structurally combined chain; R2 is (B), and X is O, S, N or NH or —CONR—, Z is O, S, N or NH, and X is different from Z; R is a fatty chain, an aromatic group, a sterically hindered amine or sterically hindered phenol, R3 is a fatty chain, an aromatic group, a sterically hindered amine or sterically hindered phenol, and R is identical to R3, or R is different from R3; n is a positive integer including 1, n1 is a positive integer including 1, and n is identical to n1, or n is different from n1.

Disclosed is an anti-oxidation stabilizer, which has the following structure (A), wherein R1 is a connection chain, and the connection chain is a fatty chain, an aromatic structural chain or a fatty and aromatic structurally combined chain; R2 is (B), and X is O, S, N or NH or —CONR—, Z is O, S, N or NH, and X is different from Z; R is a fatty chain, an aromatic group, a sterically hindered amine or sterically hindered phenol, R3 is a fatty chain, an aromatic group, a sterically hindered amine or sterically hindered phenol, and R is identical to R3, or R is different from R3; n is a positive integer including 1, n1 is a positive integer including 1, and n is identical to n1, or n is different from n1.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

Disclosed herein are compositions and methods of making phenolic compounds, and resins comprising these phenolic compounds. The compounds include multifunctional epoxies, amino glycidyl derivatives, and multi-functional amines prepared from hydroxymethyl derivatives of phenols and bisphenols

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.